Jurgen Vercauteren

List of Publications by Year
in descending order

42 papers	2,020 citations	304368 22 h-index	276539 41 g-index
45 all docs	45 docs citations	45 times ranked	3185 citing authors

#	Article	IF	Citations
1	Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis. Lancet Infectious Diseases, The, 2019, 19, 143-155.	4.6	255
2	Transmission of Drug‐Resistant HIV‐1 Is Stabilizing in Europe. Journal of Infectious Diseases, 2009, 200, 1503-1508.	1.9	213
3	Relating increasing hantavirus incidences to the changing climate: the mast connection. International Journal of Health Geographics, 2009, 8, 1.	1.2	198
4	Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Supportive Care in Cancer, 2011, 19, 1753-1760.	1.0	133
5	HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology, 2013, 10, 7.	0.9	129
6	Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. Aids, 2008, 22, 625-635.	1.0	109
7	Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health, 2014, 14, 1035.	1.2	82
8	Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia. Journal of Infectious Diseases, 2015, 211, 1735-1744.	1.9	62
9	The global spread of HIV-1 subtype B epidemic. Infection, Genetics and Evolution, 2016, 46, 169-179.	1.0	60
10	Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania. BMC Public Health, 2013, 13, 38.	1.2	58
11	CRF19_cpx is an Evolutionary fit HIV-1 Variant Strongly Associated With Rapid Progression to AIDS in Cuba. EBioMedicine, 2015, 2, 244-254.	2.7	56
12	Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antiviral Research, 2006, 71, 335-342.	1.9	54
13	Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey. Lancet HIV,the, 2020, 7, e772-e781.	2.1	51
14	Higher proportion of G2P[4] rotaviruses in vaccinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine effectiveness against heterotypic G2P[4] rotaviruses. Clinical Microbiology and Infection, 2014, 20, O702-O710.	2.8	50
15	The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001–2006) in Portugal. Retrovirology, 2008, 5, 12.	0.9	43
16	Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infectious Diseases, 2014, 14, 407.	1.3	43
17	HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir. Antimicrobial Agents and Chemotherapy, 2013, 57, 1053-1056.	1.4	39
18	Trends and Predictors of Transmitted Drug Resistance (TDR) and Clusters with TDR in a Local Belgian HIV-1 Epidemic. PLoS ONE, 2014, 9, e101738.	1.1	36

#	ARTICLE	IF	CITATIONS
19	Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Antiviral Therapy, 2009, 14, 433-442.	0.6	35
20	Prevalence and Epidemiology of HIV Type 1 Drug Resistance among Newly Diagnosed Therapy-Naive Patients in Belgium from 2003 to 2006. AIDS Research and Human Retroviruses, 2008, 24, 355-362.	0.5	33
21	Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group. PLoS ONE, 2014, 9, e94495.	1.1	32
22	Evolutionary analysis of HBV â€œSâ€•antigen genetic diversity in Iranian blood donors: A nationwide study. Journal of Medical Virology, 2014, 86, 144-155.	2.5	28
23	Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. Retrovirology, 2012, 9, 81.	0.9	23
24	Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Antiviral Therapy, 2009, 14, 433-42.	0.6	19
25	Predictors of non adherence to antiretroviral therapy at an urban HIV care and treatment center in Tanzania. Drug, Healthcare and Patient Safety, 2018, Volume 10, 79-88.	1.0	18
26	Behavioral changes before lockdown and decreased retail and recreation mobility during lockdown contributed most to controlling COVID-19 in Western countries. BMC Public Health, 2021, 21, 654.	1.2	18
27	Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response. PLoS ONE, 2013, 8, e61436.	1.1	17
28	A Fashi Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated Neuroinflammation. Frontiers in Immunology, 2017, 8, 97.	2.2	14
29	Singleâ€•and multipleâ€•dose pharmacokinetics and safety of pimodivir, a novel, nonâ€•nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 openâ€•label study in healthy volunteers. British Journal of Clinical Pharmacology, 2018, 84, 2663-2672.	1.1	13
30	Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 587-599.	0.7	12
31	Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe. Journal of Antimicrobial Chemotherapy, 2015, 70, 1850-7.	1.3	12
32	Comprehensive Antiretroviral Restriction Factor Profiling Reveals the Evolutionary Imprint of the ex Vivo and in Vivo IFN-Î² Response in HTLV-1-Associated Neuroinflammation. Frontiers in Microbiology, 2018, 9, 985.	1.5	12
33	Cellular HIV-1 DNA Levels in Drug Sensitive Strains Are Equivalent to Those in Drug Resistant Strains in Newly-Diagnosed Patients in Europe. PLoS ONE, 2010, 5, e10976.	1.1	10
34	Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G. Infection, Genetics and Evolution, 2010, 10, 373-379.	1.0	9
35	The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovirâ˜†. Infection, Genetics and Evolution, 2009, 9, 683-688.	1.0	8
36	Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania. Journal of Infection in Developing Countries, 2014, 8, 845-852.	0.5	8

#	Article	IF	Citations
37	HIV-1 transmitted drug resistance in Latin America and the Caribbean: what do we know?. AIDS Reviews, 2012, 14, 256-67.	0.5	8
38	The demise of multidrug-resistant HIV-1: the national time trend in Portugal. Journal of Antimicrobial Chemotherapy, 2013, 68, 911-914.	1.3	6
39	Phenotypical and Functional Characterization of Neutrophils in Two Pyrin-Associated Auto-inflammatory Diseases. Journal of Clinical Immunology, 2021, 41, 1072-1084.	2.0	6
40	HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure. Infection, Genetics and Evolution, 2013, 19, 349-360.	1.0	4
41	Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. Journal of Antimicrobial Chemotherapy, 2013, 68, 419-423.	1.3	4
42	Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas. International Journal of Molecular Sciences, 2021, 22, 10568.	1.8	0